Related Experiment Video
Updated: Oct 13, 2025
07:26
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
17.9K
Βeta-2-glycoprotein I exerts antithrombotic function through its domain V in mice
Freda H Passam1, Gang Chen2, Vivien M Chen3
1Faculty Medicine Health, University of Sydney, Sydney, Australia; Heart Research Institute, Sydney, Australia.
Journal of Autoimmunity
|November 18, 2021
Summary
Beta-2-glycoprotein I (β2GPI) acts as a natural anticoagulant, reducing thrombus formation. Its fifth domain is crucial for this antithrombotic effect, suggesting potential therapeutic applications.
Area of Science:
- Biochemistry
- Hematology
- Immunology
Background:
- The physiological role of beta-2-glycoprotein I (β2GPI) remains largely unknown, despite its significance as a major auto-antigen in antiphospholipid syndrome.
- A comprehensive in vivo investigation into β2GPI's role in thrombus formation has been lacking.
Purpose of the Study:
- To systematically investigate the role of β2GPI in thrombus formation in vivo.
- To determine the specific domain of β2GPI responsible for its antithrombotic activity.
Main Methods:
- Utilized a laser-induced arteriole and venule thrombosis model in β2GPI deficient (-/-) and wild type (WT) mice.
- Administered human recombinant β2GPI domain deletion mutants (lacking domain V) and human recombinant domain V intravenously.
- Assessed thrombus size, platelet aggregation, and fibrin deposition.
Main Results:
- β2GPI deficient mice exhibited enhanced thrombus formation compared to WT mice.
- Neutrophil accumulation and elastase activity were increased in thrombi of β2GPI -/- mice.
- Administration of domain V significantly inhibited thrombus formation in both β2GPI -/- and WT mice, while domain I-IV had no effect.
Conclusions:
- β2GPI functions as a significant natural anticoagulant, playing a key role in regulating thrombus formation.
- The fifth domain of β2GPI is essential for its antithrombotic properties.
- β2GPI domain V holds promise as a potential therapeutic target for antithrombotic strategies.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.0K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
735
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
735
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
01:29Venous Thrombosis III: Interprofessional Care
57
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
57
01:16Clot Retraction and Fibrinolysis
7.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.4K